title: [Interferon and interleukin 2 in metastatic cancer of the kidney. Apropos of 18 cases].
abstract: Eighteen patients with advanced renal cancer received a combination of IFN alpha 10 x 10(6) U/m2/Day (D) x 5D followed by Interleukin 2 (IL2) 18 x 10(6) UI/m2/D x 5 D. The median follow-up is 10 months. Four partial responses were observed lasting 7 to 13 months (22.2%). The clinical safety was satisfactory. The survival for responding patients is 12 months (median). The safety of treatment is an argument in favour of future trials in an attempt to demonstrate the benefit of combinations of biomodulators.
authors.affiliation: Service d'Oncologie Médicale, Hôpital Avicenne, Bobigny.
authors.forename: C
authors.initials: C
authors.lastname: Boaziz
authors.forename: J L
authors.initials: JL
authors.lastname: Breau
authors.forename: J F
authors.initials: JF
authors.lastname: Morère
authors.forename: E
authors.initials: E
authors.lastname: Raymond
authors.forename: M
authors.initials: M
authors.lastname: Moliard
authors.forename: L
authors.initials: L
authors.lastname: Israel
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001663:Bilirubin / Q000097:blood; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000601:surgery; D008175:Lung Neoplasms / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D012074:Remission Induction
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2; D003404:Creatinine; D000469:Alkaline Phosphatase; D001663:Bilirubin
vernacular_title: Interféron et interleukine 2 dans le cancer du rein métastasé. A propos de dix-huit cas.